You are here

Transdermal Patch Shows Promise in Parkinson’s Disease

Higher systemic exposure with rasagiline patch versus tablets

Positive results have been reported from a recently completed bioavailability study that examined the delivery of TPU-002RA (Teikoku Pharma USA), a 7-day rasagiline patch, for patients with Parkinson’s disease (PD). The study was part of the FDA’s recommended program for a new drug application (NDA) for TPU-002RA and will be a critical component of the product’s NDA.

TPU-002RA is a transdermal patch system that contains the same active drug component in Azilect (Teva Pharmaceuticals), the only currently marketed form of rasagiline. In the new study, one patch of rasagiline applied for 7 days achieved a higher systemic exposure than that of rasagiline 1-mg tablets (Azilect) administered orally once daily for 7 days. In addition, the patch produced more-consistent blood levels of rasagiline throughout the 7-day period without significant peaks, which were seen with the oral product.

PD is the second most common neurodegenerative disease after Alzheimer’s disease, affecting between 1.0 million and 1.5 million Americans. The primary symptoms of the disorder (stiffness, tremors, and slowed movements and gait) are caused by a loss of dopamine production by the neurons that are involved in controlling movement and coordination.

In addition to the need to develop a therapy to slow the progression of PD, several other important needs exist:

  • Alternative delivery systems to counter difficulty swallowing
  • New drugs to delay the onset of dementia with fewer adverse effects
  • A “cure” that repairs and/or reverses the neural damage
  • Simplification of complex medical regimens

Source: PR Newswire; December 2, 2014.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential